University of Montpellier, Institut des Biomolécules Max Mousseron, UMR 5247 CNRS UM ENSCM). Research activities of IBMM lie at the interface between chemistry and biology aiming to study and gain insight into the mechanims of action of biomolecules and the treatment of human and animal pathologies (infectious, cardio-vascular, degenerative, cancer...) with applications for tomorrow’s molecular medicine. SITE WEB : http://ibmmpeptide.com/ POSTE ET MISSIONS The post-doctoral research assistant will be in charge of the development of proteolysis targeted chimera (PROTAC) molecules with potential applications in DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). DIPG is an incurable pediatric cancer characterized by epigenetic alterations and abnormal activation of several KINASE RECEPTORS. Small molecule inhibitors targeting these mutations were developed but did not show sufficient efficacy in DIPG. Thus, the objective of this project is to develop PROTAC derivatives with enhanced properties exploiting these targets. Synthesis of inhibitors, optimization of the LINKER PART of the PROTACs and study of different RECRUITING ELEMENTS will allow to constitute several LIBRARIES OF PROTAC. We have partnered with a biology team interested in the development of innovative therapies in DIPG in order to test these PROTAC compounds and validate their efficacy _in vitro_ (alone or in combination). Their ability to cross the blood-brain barrier and their ability to eliminate DIPG cells _in vivo_ will also be explored. MOBILITÉ GÉOGRAPHIQUE : Pas de déplacement PRISE DE FONCTION : 16/05/2022 PROFIL The post-doc fellowship is granted by the French National Institute of Cancer (INCa) for 12 MONTHS. The contract could be possibly extended. Candidates should have a PhD and strong skills in Organic Chemistry. An experience in Medicinal Chemistry is not required but would be appreciated.